Bosentan potentially cost effective in PAH

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.512, 2006-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bosentan potentially cost effective in PAH

Inpharma, Vol. 1, Iss. 1556, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Long-term bosentan effective in paediatric PAH

Inpharma, Vol. 1, Iss. 1505, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Initiating inhaled iloprost for PAH cost effective in Spain

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 653, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite